Systemic transplantation of human BM-MSCs and stem cells from exfoliated deciduous teeth into MRL/lpr mice has been shown to enhance the functionality of damaged BM-MSCs by inhibiting IL-17, thereby restoring the balance between osteoblasts and osteoclasts and maintaining normal bone metabolism, which alleviates secondary osteoporosis.240 In another model of secondary osteoporosis, systemic infusion of BM-MSCs into mice with dexamethasone-induced osteoporosis demonstrated that these cells can home to and inhabit the bone marrow for at least four weeks.241. Here, IL17A is linked to osteoporosis.